DAI Neurology and Psychiatry, Department of Neurosurgery, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Neuroscience Department, University of Siena, Siena, Italy.
Neurol Sci. 2018 Apr;39(4):671-677. doi: 10.1007/s10072-017-3220-2. Epub 2018 Jan 30.
Despite review papers claim for radical treatment of oligometastatic patients, only few surgical series have been published. In this study, we analyze results and actual role of surgical resection for the management of patients with multiple brain metastases. This retrospective study compares surgical results of two groups of patients consecutively treated in our Institute from January 2004 to June 2015. The first group comprises all 32 patients with multiple brain metastases with only 2-3 lesions who underwent surgical resection of all lesions; the second group comprises 30 patients with a single surgically treated brain mestastasis compatible with the first group (match-paired control series). Median survival was 14.6 months for patients with multiple brain metastases (range 1-28 months) and 17.4 months for patients with a single brain metastasis (range 4-38 months); the difference was not statistically significant (P = 0.2). Neurological condition improved in 59.4% of patients with multiple metastases, it remained unchanged in 37.5% and worsened in 3.1%. In our series, selected patients with only 2-3 lesions with well-controlled systemic disease, life expectancy of more than 3 months, Karnofsky's performance status > 60, and surgically accessible lesions, benefited from surgical treatment in terms of survival and quality of life, with reduction or disappearance of significant neurological deficits. The prognosis for these patients is similar to that of patients with a single metastasis. It seems that patients with breast cancer included in our series had the worst prognosis if compared to other histotypes.
尽管综述文献主张对寡转移患者进行激进治疗,但仅有少数外科系列研究发表。在这项研究中,我们分析了手术切除治疗多发性脑转移患者的结果和实际作用。本回顾性研究比较了 2004 年 1 月至 2015 年 6 月期间在我们研究所连续治疗的两组患者的手术结果。第一组包括所有 32 名仅存在 2-3 个病变的多发性脑转移患者,他们接受了所有病变的手术切除;第二组包括 30 名具有单个可手术治疗的脑转移灶的患者,与第一组相匹配(配对对照系列)。多发性脑转移患者的中位生存时间为 14.6 个月(范围 1-28 个月),单个脑转移患者的中位生存时间为 17.4 个月(范围 4-38 个月);差异无统计学意义(P=0.2)。多发性转移患者中 59.4%的神经状况改善,37.5%的患者无变化,3.1%的患者恶化。在我们的系列研究中,对于仅有 2-3 个病变、全身疾病控制良好、预期寿命超过 3 个月、Karnofsky 表现状态>60 分且可手术切除病变的选定患者,手术治疗在生存和生活质量方面受益,显著神经功能缺损减少或消失。这些患者的预后与单发转移患者相似。与其他组织类型相比,似乎包括在我们系列中的乳腺癌患者的预后最差。